Frequently Asked Questions
The market is segmented based on , By Treatment Type (Laser Surgery, Vitrectomy, Intraocular Steroid Injection, Anti-Vascular Endothelial Growth Factor Drug), Type (Non-Proliferative, Proliferative), Device Type (Focal Laser Treatment, Vitrectomy Devices, Scatter Laser Treatment), Severity (Mild, Moderate, Severe), Drug Type (Aflibercept, Bevacizumab, Fluocinolone, Ranibizumab, Triamcinolone Acetonide Injection), End User (Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers) – Industry Trends and Forecast to 2030.
.
The Global Diabetic Retinopathy Treatment Market size was valued at USD 7.05 USD Billion in 2022.
The Global Diabetic Retinopathy Treatment Market is projected to grow at a CAGR of 6.9% during the forecast period of 2023 to 2030.
The major players operating in the market include
- Bayer AG
- Aurobindo Pharma
- AbbVie
- Novartis AG
- F. Hoffmann-La Roche Ltd
- Bausch Health Companies
- Accord Healthcare
- Genentech ,
- Regeneron Pharmaceuticals ,
- Abbott
- Kowa Pharmaceuticals America
- Ampio Pharmaceuticals
- Lumenis Be Ltd
- Alimera Sciences Europe Ltd
- Glycadia ,
- Oxurion NV,
.
The market report covers data from the U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
